This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

VIVUS Announces Scientific Presentations

MOUNTAIN VIEW, Calif., May 22, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today announced the following scientific presentations:


2013 Annual Scientific Meeting of the American Society of Hypertension (ASH) May 15-18, 2013 San Francisco Marriott, San Francisco, CA

Date / Time

Oral Presentation Date: Saturday, May 18, 2013 at 8:30am Session Location: San Francisco Marriott, Yerba Buena Ballroom 9

Presentation Title

Cardiovascular Effects Based on Magnitude of Weight Loss in Obese/Overweight Subjects With Hypertension Receiving Phentermine and Topiramate Extended-Release


George Bakris, MD, FASH, FASN a; Michael H. Davidson, MD, FACC, FACP a; Alok K. Gupta, MD, FTOS, FASH, FAAFP b


aASH Comprehensive Hypertension Center, The University of Chicago Pritzker School of Medicine, Chicago, IL; bClinical Research, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA


166 th Annual Meeting of the American Psychiatric Association (APA) May 18-22, 2013 Moscone Center, San Francisco, CA

Date / Time

Poster Presentation Date: Monday, May 20, 2013 from 2:00pm-4:00pm Session Location: Moscone South Exhibit Hall A-C Poster Session: 9 Poster number: NR9-54

Presentation Title

Weight Loss and Depression in Overweight/Obese Subjects With a History of Depression Receiving Phentermine and Topiramate Extended-Release


Patrick M. O'Neil, PhD a; Craig A. Peterson, MS b


a Medical University of South Carolina, Charleston, SC; bVIVUS, Inc., Mountain View, CA


18 th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) May 18-22, 2013 Sheraton New Orleans, New Orleans, LA, USA


Date / Time

Poster Presentation Date: Monday, May 20, 2013 from 3:45pm – 7:45 pm with discussion hour from 6:45pm-7:45pm Poster Session: II Poster Number: PSY13

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.85 -0.18%
FB $98.65 -5.20%
GOOG $671.88 -1.70%
TSLA $147.87 -9.10%
YHOO $27.00 -3.50%


Chart of I:DJI
DOW 15,832.24 -372.73 -2.30%
S&P 500 1,833.40 -46.65 -2.48%
NASDAQ 4,229.4770 -133.6670 -3.06%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs